HIGHFDA DRUG

ATORVASTATIN CALCIUM Tablets 10 mg Recall: 141,984 Bottles Nationwide (2025)

Ascend Laboratories, Parsippany, NJ is recalling 141,984 bottles of ATORVASTATIN CALCIUM Tablets USP, 10 mg, nationwide, manufactured by Alkem Laboratories, Ltd. in India. The issue is failed dissolution specifications, which could lead to improper dosing. Healthcare providers and patients should stop using the product and contact Ascend Laboratories for guidance.

Official notice
ATORVASTATIN CALCIUMAscend LaboratoriesHealth & Personal CareDrugs & Medications90-count bottle (NDC 67877-511-90)500-count bottle (NDC 67877-511-05)1000-count bottle (NDC 67877-511-10)

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
September 19, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
September 19, 2025
Hazard Level
HIGH
Brands
ATORVASTATIN CALCIUM, Ascend Laboratories
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
ATORVASTATIN CALCIUM, Ascend Laboratories
Product type
Atorvastatin Calcium Tablets USP, 10 mg
Model numbers
90-count bottle (NDC 67877-511-90), 500-count bottle (NDC 67877-511-05), 1000-count bottle (NDC 67877-511-10), Lot#: 25141249, Exp. Feb. 2027 Lot#: 24144938, Exp. Nov. 2026 Lot#: 24144868, Exp. Nov. 2026 Lot#: 24144867, Exp. Nov. 2026 Lot#: 24144458 +4 more
UPC codes
67877-511, 67877-512, 67877-513, 67877-514, 67877-511-90, 67877-511-05, 67877-511-10, 67877-511-55 +6 more
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    September 19, 2025

  2. Reported by FDA DRUG

    October 22, 2025

  3. RecallRadar source check

    April 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Failed Dissolution Specifications

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Ascend Laboratories, LLC or your healthcare provider for guidance. Notification method: Letter

About This Product

This medication is a generic statin used to lower cholesterol. It is distributed nationwide for adults with elevated cholesterol or cardiovascular risk.

Why This Is Dangerous

A failed dissolution specification means the tablet could fail to release the active drug as intended, leading to reduced or inconsistent drug exposure.

Industry Context

This recall is not described as part of a broader industry pattern in the notice.

Real-World Impact

Patients may experience reduced therapeutic effect or require dosage adjustments. The recall is high risk but no injuries have been reported.

Practical Guidance

How to identify if yours is affected

  1. Verify bottle size: 90-count, 500-count, or 1000-count.
  2. Note Lot numbers listed in the recall information and compare to your bottle.

Where to find product info

NDC is printed on the bottle label. Lot numbers appear on the bottle or packaging. Expiration dates are listed on the label.

What timeline to expect

Refunds or replacements timelines are not specified in the recall; follow-up from Ascend Laboratories or the FDA may provide guidance.

If the manufacturer is unresponsive

  • File a report with FDA MedWatch at 1-800-FDA-1088 if the company is unresponsive.
  • Consult your pharmacist or physician for interim guidance.

How to prevent similar issues

  • Verify NDC before purchasing similar statin medications.
  • Buy from reputable pharmacies and confirm packaging integrity.
  • Discuss any recalls with your healthcare provider at your next visit.

Documentation advice

Keep the recall notice, bottle labels, NDCs, lot numbers, and any correspondence with Ascend Laboratories. Photograph the bottle and label for records.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Product: ATORVASTATIN CALCIUM Tablets USP, 10 mg; NDCs: 67877-511-90 (90-count), 67877-511-05 (500-count), 67877-511-10 (1000-count); Lot numbers include 25141249 and 2414-series with Exp dates: Feb 2027, Nov 2026, Sep 2026, Jul 2026, among others; Distributed nationwide in the United States; Manufactured by Alkem Laboratories, Ltd. India; Distributed by Ascend Laboratories, LLC, Parsippany, NJ 07054; Recall date: 2025-09-19; Status: ACTIVE; Quantity: 141,984 bottles.

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • 141,984 bottles recalled nationwide
  • Bottle sizes: 90-count, 500-count, 1000-count
  • Manufactured by Alkem Laboratories, Ltd. India
  • Distributed by Ascend Laboratories, LLC, Parsippany, NJ 07054
  • Hazard: Failed dissolution specifications

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product TypeAtorvastatin Calcium Tablets USP, 10 mg
Sold At
Multiple Retailers

Product Details

Model Numbers
90-count bottle (NDC 67877-511-90)
500-count bottle (NDC 67877-511-05)
1000-count bottle (NDC 67877-511-10)
Lot#: 25141249
Exp. Feb. 2027 Lot#: 24144938
+7 more
UPC Codes
67877-511
67877-512
67877-513
+11 more
Affected States
ALL
Report Date
October 22, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls